NIH begins clinical trial of live, attenuated Zika vaccine
Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the NIAID. The trial will enroll a total of 28 healthy, non-pregnant adults ages 18 to 50. NIAID is sponsoring the trial. August 16, 2018